{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '109', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.2', 'Responsibility for Analyses/In-house Blinding', 'Note: As of Amendment 007-06, the study is unblinded to the Sponsor, the', 'investigational sites, and the participants. This section has been updated accordingly.', 'The statistical analysis of the data obtained from this study will be the responsibility of the', 'Clinical Biostatistics department of the Sponsor.', 'This study was conducted as a double-blind study under in-house blinding procedures until', 'after the eDMC recommended study unblinding.', 'The Sponsor generated the randomized allocation schedule(s) for study intervention', 'assignment. Blinding issues related to the planned interim analyses are described in Section', '9.7, but are no longer applicable as of Amendment 007-06.', 'Extension Study in China', 'For all participants in China, including participants randomized in the global study and the', 'extension study, statistician(s)/programmers were blinded to participant level treatment', 'randomization and this information had been clearly documented.', '9.3', 'Hypotheses/Estimation', 'Objectives and hypotheses of the study are stated in Section 3.', '9.4', 'Analysis Endpoints', 'Efficacy and safety endpoints that will be evaluated for within- and/or between-treatment', 'differences are listed below.', '9.4.1', 'Efficacy Enppoints', '9.4.1.1', 'Primary Enppoints', 'PFS: the time from randomization to the first documented PD per RECIST 1.1, adjusted to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, based', 'on BICR or death due to any cause, whichever occurs first. See Section 9.6.1 for the', 'definition of censoring.', 'OS: the time from randomization to death due to any cause.', '9.4.1.2', 'Secondary Enppoints', 'OR: a confirmed CR or PR per RECIST 1.1, adjusted to follow a maximum of 10 target', 'lesions and a maximum of 5 target lesions per organ, based on BICR.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '110', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.4.1.3', 'Exploratory Enppoints', 'DOR: the time from the earliest date of qualifying response until earliest date of PD or death', 'from any cause, whichever comes first.', '9.4.2', 'Safety Enppoints', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, SAEs, fatal AEs, laboratory tests, and vital signs. Furthermore, specific events will be', 'collected and designated as ECIs as described in Section 8.4.7.', '9.4.3', 'Patient-reported Outcome Enppoints', 'The following secondary PRO endpoints will be evaluated as described in Section 4.2.1.3', 'and analyzed as described in Section 9.6.3:', 'Change from baseline in', 'Global Health Status/QoL scale (QLQ-C30 items 29-30)', 'Single-item symptom scales: cough (QLQ-LC13 item 31), chest pain (QLQ-LC13', 'item 40), and dyspnea (QLQ-C30 item 8)', 'Physical functioning scale (QLQ-C30 items 1-5)', 'Time to true deterioration (TTD) in', 'Global Health Status/QoL scale (QLQ-C30 items 29-30)', 'Single-item symptom scales: cough (QLQ-LC13 item 31), chest pain (QLQ-LC13', 'item 40), and dyspnea (QLQ-C30 item 8)', 'Physical functioning scale (QLQ-C30 items 1-5)', 'Composite symptom endpoint: cough (QLQ-LC13 item 31), chest pain (QLQ-LC13', 'item 40), or dyspnea (QLQ-C30 item 8)', 'The TTD in global health status/QoL, cough, chest pain, dyspnea, and physical functioning is', 'defined as the time from baseline to the first onset of a 10 or more points deterioration from', 'baseline with confirmation by the subsequent visit of a 10 or more points deterioration from', 'baseline. The TTD in the composite endpoint of cough, chest pain, or dyspnea is defined as', 'the time to first onset of 10 or more points deterioration from baseline in any one of 3 scale', 'items with confirmation by the subsequent visit of 10 points or more deterioration from', 'baseline in the same scale as the first onset. The EQ-5D-5L will be evaluated as an', 'exploratory endpoint. These analyses and other supportive PRO analyses will be described in', 'the sSAP.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}